The Legal and Ethical Dimensions of Hospital Visitation Bans in the COVID-19 Era.

Publication date: Jan 31, 2025

Background/Objectives: The COVID-19 pandemic compelled countries worldwide to implement stringent visitation restrictions across hospitals, nursing homes, and long-term care facilities to mitigate viral transmission. While initially justified by the uncertainty surrounding the virus, these restrictions often lasted well beyond the acute stage of the pandemic, leading to substantial psychological and physical harm, particularly for older adults. This study assesses the effects of these controls and offers strategies to balance public health priorities with patients’ rights and psychological well-being during public health crises. Methods: An integrative review and comparative analysis of legislative measures and the psychological effects of visitation restrictions was undertaken. International and national visitation regulations and case studies were reviewed, and ethical frameworks were considered. Results: Our findings indicate that prolonged isolation due to extended visitation restrictions led to higher rates of anxiety, depression, and delirium among patients, creating ethical dilemmas for healthcare providers. Legal responses to this challenge varied globally. International human rights organizations called for policies bridging public health priorities with patients’ rights to family and caregiver support. Some U. S. states enacted proactive legislation to strengthen family visitation rights, while other jurisdictions lack these visitation protections. Conclusions: Prolonged visitation restrictions during the pandemic show the need for legislation integrating public health protections with in-person family and caregiver support. The ethical imperatives of limiting the psychological harm caused by healthcare isolation and the legislative solutions to protect public health and the psychological well-being of patients during health crises are discussed.

Open Access PDF

Concepts Keywords
Basel emergency decrees
Hospitals healthcare regulation
Pandemic human rights law
Proactive patient visitation rights
Viral public health legislation

Semantics

Type Source Name
disease MESH COVID-19
disease MESH uncertainty
drug DRUGBANK Isoxaflutole
disease MESH psychological well-being
disease MESH anxiety
disease MESH depression
disease MESH delirium
drug DRUGBANK Coenzyme M
drug DRUGBANK Cysteamine
disease MESH emergency
drug DRUGBANK Etoperidone
disease MESH end of life
disease MESH cognitive impairments
disease MESH infection
disease MESH psychological distress
disease IDO facility
disease MESH privacy
disease MESH loneliness
disease MESH critically ill
disease MESH suicidal ideation
disease MESH inflammation
disease MESH memory loss
disease MESH complications
disease MESH compassion fatigue
disease IDO quality
drug DRUGBANK Methylergometrine
disease MESH PTSD
drug DRUGBANK Spinosad
disease MESH infectious diseases
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Viral Infections
disease MESH Cerebrovascular Stroke
drug DRUGBANK Guanosine
disease IDO intervention
disease MESH Syndrome
drug DRUGBANK Etodolac
disease MESH Morbidity
disease MESH Dissociation
disease MESH Alzheimer’s Disease
drug DRUGBANK Vorinostat
drug DRUGBANK (S)-Des-Me-Ampa

Original Article

(Visited 1 times, 1 visits today)